Cleveland BioLabs Overview
Cleveland BioLabs (CBLI) has a ROE of -30.78%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow-30.78%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cleveland BioLabs (CBLI) currently reports a ROE of -30.78%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Cleveland BioLabs's ROE history and peer comparisons.
Cleveland BioLabs's ROE of -30.78% is lower than the Healthcare sector average of 29.33%. That is roughly 204.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cleveland BioLabs's current -30.78% should be judged against Healthcare norms (sector average: 29.33%) and against CBLI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -30.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Cleveland BioLabs, and consider following CBLI for alerts when major investors trade the stock.
Cleveland BioLabs is classified in the Healthcare sector. On ROE, it currently shows -30.78% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBLI with unrelated industries.
